A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Digoxin has been studied across 12 research domains including ❤️ Cardiovascular, 🧠 Focus & Attention, 🫘 Kidney, 😴 Sleep, ⚡ Energy & Fatigue. The primary research focus is ❤️ Cardiovascular with 28% of studies addressing this area.
The following compounds share molecular targets with Digoxin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Digoxin is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.